Abstract
It is now recognized that inflammatory processes regulate all stages of atherosclerosis, from disease initiation to thrombotic complications. C-reactive protein (CRP) is a plasmatic protein used as a general marker of inflammation. The high sensitivity C-reactive protein (hsCRP) refers to the measurement of CRP in blood samples using assays with sufficient sensitivity to quantify low (baseline) levels of this biomarker. Low-grade chronic inflammatory processes are linked to atherosclerosis and may be screened with the use of hsCRP, thus providing additional information in cardiovascular risk prediction. This review elaborates the role of CRP in atherogenesis and the value of hsCRP as a biomarker in cardiovascular risk prediction in both primary and secondary prevention setting.
Keywords: Atherogenesis, biomarker, cardiovascular disease, C-reactive protein, high sensitivity C-reactive protein, inflammation, prevention.
Current Pharmaceutical Analysis
Title:High Sensitivity C-reactive Protein and Cardiovascular Risk Prediction
Volume: 11 Issue: 1
Author(s): Andreja Trpkovic, Julijana Stanimirovic, Ivana Resanovic, Petar Otasevic, Danimir Jevremovic, Radak Djordje and Esma R. Isenovic
Affiliation:
Keywords: Atherogenesis, biomarker, cardiovascular disease, C-reactive protein, high sensitivity C-reactive protein, inflammation, prevention.
Abstract: It is now recognized that inflammatory processes regulate all stages of atherosclerosis, from disease initiation to thrombotic complications. C-reactive protein (CRP) is a plasmatic protein used as a general marker of inflammation. The high sensitivity C-reactive protein (hsCRP) refers to the measurement of CRP in blood samples using assays with sufficient sensitivity to quantify low (baseline) levels of this biomarker. Low-grade chronic inflammatory processes are linked to atherosclerosis and may be screened with the use of hsCRP, thus providing additional information in cardiovascular risk prediction. This review elaborates the role of CRP in atherogenesis and the value of hsCRP as a biomarker in cardiovascular risk prediction in both primary and secondary prevention setting.
Export Options
About this article
Cite this article as:
Trpkovic Andreja, Stanimirovic Julijana, Resanovic Ivana, Otasevic Petar, Jevremovic Danimir, Djordje Radak and Isenovic R. Esma, High Sensitivity C-reactive Protein and Cardiovascular Risk Prediction, Current Pharmaceutical Analysis 2015; 11 (1) . https://dx.doi.org/10.2174/1573412910666140822003911
DOI https://dx.doi.org/10.2174/1573412910666140822003911 |
Print ISSN 1573-4129 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-676X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cell Therapy for Myocardial Regeneration
Current Molecular Medicine The Use of Infliximab in Dermatology
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Lock Stock and Barrel of Wound Healing
Current Pharmaceutical Design Non-Communicable Diseases and Adherence to Mediterranean Diet
Endocrine, Metabolic & Immune Disorders - Drug Targets CRISPR-cas System as a Genome Engineering Platform: Applications in Biomedicine and Biotechnology
Current Gene Therapy The Impact of Uncontrolled Hypertension on the Longitudinal Systolic Function of the Left Ventricle
Current Hypertension Reviews Gene Therapy Targeting Inflammation in Atherosclerosis
Current Pharmaceutical Design Lipids in the Diet and the Fatty Acid Profile in Beef: A Review and Recent Patents on the Topic
Recent Patents on Food, Nutrition & Agriculture The Function of LncRNA FTX in Several Common Cancers
Current Pharmaceutical Design Atrial Fibrillation with a Focus on Oral Antiarrhythmic Therapy
Current Drug Therapy Human Endotoxemia as a Model of Systemic Inflammation
Current Medicinal Chemistry Females Live Longer than Males: Role of Oxidative Stress
Current Pharmaceutical Design DYRK1A: A Potential Drug Target for Multiple Down Syndrome Neuropathologies
CNS & Neurological Disorders - Drug Targets Resistance to Aspirin and Thienopyridines in Diabetes Mellitus and Metabolic Syndrome
Current Vascular Pharmacology Stress Hormone-Mediated DNA Damage Response -- Implications for Cellular Senescence and Tumour Progression
Current Drug Targets Editorial (Hot Topic: Novel Biomarkers in the Prognosis, Progression and Treatment of Cardiovascular Disease: The Role of microRNAs )
Current Topics in Medicinal Chemistry The First Line of Defense Against Cardiac Hypertrophy
Current Molecular Medicine Psychosocial Implications During Adolescence for Infant Heart Transplant Recipients
Current Cardiology Reviews Gene-Nutrient Interaction in Type 2 Diabetes: An Appraisal of the Role of the Peroxisome Proliferator-Activated Receptor Pathway
Current Pharmacogenomics Role of PPAR in Cardiovascular Diseases
Recent Patents on Cardiovascular Drug Discovery